Koh YW, Jung SJ, Park CS, et al. LGALS3 as a prognostic factor for classical Hodgkin's lymphoma. Mod Pathol. 2014,27(10):1338-1344.
Abstract
LGALS3, a member of the lectin family, has an important role in tumor progression through inhibition of apoptosis. LGALS3 shares several significant structural properties with BCL2. In this study, we examined the prognostic significance of LGALS3 and BCL2 in uniformly treated classical Hodgkin's lymphoma. Diagnostic tissues from 110 patients with uniformly treated classical Hodgkin's lymphoma were evaluated retrospectively by immunohistochemical analysis of LGALS3 and BCL2 expression. The median follow-up time was 6.2 years (range, 0.2-17.3 years). Twenty-seven patients (25%) expressed LGALS3 protein in Hodgkin/Reed-Sternberg cells, which was associated with poor overall survival and event-free survival (P=0.007 and P<0.001). Fifteen patients (14%) expressed BCL2 protein in Hodgkin/Reed-Sternberg cells, which was not associated with overall survival and event-free survival (P=0.928 and P=0.900).There was no correlation between LGALS3 and BCL2 expression (P=0.193). Multivariate analysis identified LGALS3 protein as an independent prognostic factor for event-free survival (P=0.007). Subgroup analysis according to the Ann Arbor stage of classical Hodgkin's lymphoma showed that LGALS3 protein expression had a prognostic value in limited-stage classical Hodgkin's lymphoma (P<0.001). The results of this study suggest that LGALS3 is an independent prognostic factor in classical Hodgkin's lymphoma, and may allow the identification of a subgroup of patients with limited-stage classical Hodgkin's lymphoma who require more intensive therapy.

LGALS3作为植物凝集素家族的一员，通过抑制细胞凋亡在肿瘤进展过程中扮演着重要的角色。LGALS3与BCL2共享一些重要的结构属性。本研究中，作者评估了LGALS3和BCL2在经典型霍奇金淋巴瘤中的预后意义。通过免疫组化分析LGALS3 和BCL2的表达，对110例经典型霍奇金淋巴瘤进行了回顾性的评估。随访时间0.2～17.3年，平均随访6.2年。27例（25%）R-S细胞表达LGALS3蛋白，与总生存率和无病生存率短有关（P=0.007 和 P<0.001）；15例（14%）R-S细胞表达BCL2蛋白，与总生存率和无病生存率无关（P=0.928 和 P=0.900）。LGALS3和BCL2的表达无相关性（P=0.193）。多变量分析发现LGALS3蛋白可作为无病生存率的一项独立性预后因子（P=0.007）。根据密西根大学关于经典型霍奇金淋巴瘤亚组分析显示：LGALS3蛋白的表达对于处于特定阶段的经典型霍奇金淋巴瘤有预后价值（P<0.001）。本研究结果显示：LGALS3可作为经典型霍奇金淋巴瘤独立的预后因子，可能代表处于该阶段的经典型霍奇金淋巴瘤患者需要进一步的强化治疗。